N. Girard

84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816

P.M. Forde, J. Spicer, N. Girard et al. · Journal of Thoracic Oncology · 2023 · 47 citations · Full text

Medicine, Oncology, Pharmacology +13

4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study

J.C-H. Yang, Yoon Jun Kim, SH Lee et al. · Journal of Thoracic Oncology · 2025 · 44 citations · Full text

Medicine, Oncology, Pharmacology +11

OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial

B. Besse, Giuseppe Lo Russo, H. Léna et al. · Journal of Thoracic Oncology · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacology +3

LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study

N. Girard, Mauricio Burotto, L.G. Paz-Ares et al. · Annals of Oncology · 2024 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +16